Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HPV Associated Cancer Clear all
Recruiting Phase 2 Interventional

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

NCT06445114
View directory record Official record
Conditions
Oropharyngeal Cancer, Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
Zachary Zumsteg
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Terminated Not applicable Interventional Results available

OPSCC N0 Nodal Control With Reduced IMRT

NCT01891695
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), HPV (Human Papillomavirus)-Associated
Interventions
39.6 Gy radiation
Radiation
Lead sponsor
Paul W. Read, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 25, 2026, 10:48 PM EDT
Completed No phase listed Observational

DNA Analysis of Tumor Tissue Samples From Patients With Human Papilloma Virus-Associated Cancer of the Oropharynx

NCT00897988
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene expression analysis, mutation analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 25, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT04432597
View directory record Official record
Conditions
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer, Cervical Cancer
Interventions
PRGN-2009, M7824, EKG, CT Scan, Brain MRI, Biopsy
Biological · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT07209189
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, Skull Base Tumors, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Adjuvant Radiation Therapy, Docetaxel, Cisplatin
Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)

NCT07513389
View directory record Official record
Conditions
Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Interventions
Active Surveillance With ctHPVDNA (NavDx®)
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Active, not recruiting Not applicable Interventional

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

NCT04667585
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
De-escalated radiation dose, Standard radiation dose, 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)
Radiation · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972
View directory record Official record
Conditions
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Active, not recruiting Phase 2 Interventional

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

NCT03323463
View directory record Official record
Conditions
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck
Interventions
F-FMISO PET/CT Scan, 30 Gy over 3 weeks, Cisplatin, Carboplatin, 5Fluorouracil, Proton Therapy
Diagnostic Test · Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

NCT04799054
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Interventions
TransCon TLR7/8 Agonist, Pembrolizumab
Drug
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

NCT02280811
View directory record Official record
Conditions
Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer
Interventions
Fludarabine, Cyclophosphamide, E6 TCR, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 25, 2026, 10:48 PM EDT
Withdrawn Phase 1 Interventional

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

NCT03575234
View directory record Official record
Conditions
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cyclophosphamide, IRX-2, Nivolumab, Surgery
Drug · Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 25, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Results available

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

NCT01525927
View directory record Official record
Conditions
Oropharyngeal Neoplasms
Interventions
chemotherapy, radiotherapy, Reduced dose radiotherapy
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Phase 1 Interventional

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

NCT06747390
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma (OPSCCA), Oropharyngeal Cancer, Human Papilloma Virus, Squamous Cell Carcinoma
Interventions
Lidocaine 1% Injectable Solution
Drug
Lead sponsor
Ryan Carey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional

Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly

NCT06309225
View directory record Official record
Conditions
Oropharynx Cancer, Frailty
Interventions
Modified dose and fields intensity modulated radiotherapy
Radiation
Lead sponsor
Omar Mahmoud
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 25, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Results available

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

NCT03601507
View directory record Official record
Conditions
CDKN2A-p16 Positive, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage II Oropharyngeal Squamous Cell Carcinoma AJCC V7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Alpelisib, Laboratory Biomarker Analysis, Pharmacodynamic Study, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 25, 2026, 10:48 PM EDT
Terminated Phase 1 Interventional

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

NCT01493154
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
DNA Vaccine, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2018 · Synced Sep 25, 2026, 10:48 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers

NCT05132803
View directory record Official record
Conditions
Recurrent Human Papillomavirus Type 16 Associated Cancer
Interventions
HPV 16 TA-CIN
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer

NCT06984861
View directory record Official record
Conditions
Oropharyngeal Carcinoma
Interventions
18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
Diagnostic Test · Combination Product · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

NCT03162224
View directory record Official record
Conditions
Head and Neck Cancer, Human Papilloma Virus
Interventions
MEDI0457, CELLECTRA®5P device, Durvalumab
Drug · Device
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 25, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma

NCT02163057
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
INO-3112, CELLECTRA™-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 25, 2026, 10:48 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Emergency Department-based Cervical Cancer Screening Through Self-sampling

NCT07345897
View directory record Official record
Conditions
HPV, HPV Associated Cancers, HPV Cancers, Cervical Cancer Screening, Cervical Cancer (Early Detection)
Interventions
Cervical Cancer Screening
Diagnostic Test
Lead sponsor
University of Rochester
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 25, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

NCT03077243
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Gainesville, Florida • Jacksonville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 25, 2026, 10:48 PM EDT